Schering-Plough Drug Gets Fast Track (Hepatitis C Infection)

Schering-Plough Drug Gets Fast Track
AP via Yahoo! Finance - Jan 30 6:44 AM
Drug maker Schering-Plough Corp. said Monday that regulators granted "fast track" status to its experimental hepatitis C treatment.Save to My Web

YOU ARE HERE:
Aidsmap - Jan 23 4:58 PM
Fatigue is more than twice as prevalent as depression during anti-hepatitis C (HCV) treatment in HIV-positive individuals, according to a study presented to the Second International Workshop on HIV and Hepatitis Coinfection, held in Amsterdam earlier this month.Save to My Web

Novartis and Idenix seek European approval of telbivudine (LDT600) for the ...
Financial.de - Feb 07 1:04 AM
Basel, February 7, 2006 - Novartis ( News / Kurs / Chart / Board ) and Idenix Pharmaceuticals, Inc. announced today the European submission of telbivudine (LTD600) for approval as a novel treatment for patients affected by chronic hepatitis B (CHB), a potentially fatal disease estimated to affect more than three million people in Europe1 and over 350 million people worldwide.Save to My Web

YOU ARE HERE:
Aidsmap - Jan 26 4:13 AM
Using liver biopsies the researchers established that 25% of patients with normal alanine aminotransferase (ALT) levels - a key marker of liver function have such severe liver damage that they require anti-hepatitis C treatment, with 13% having cirrhosis, permanent scarring of the liver.Save to My Web

Human Genome Sciences Reports Financial Results for Full Year and Fourth Quarter 2005
[Press Release] PR Newswire via Yahoo! Finance - Feb 09 6:38 AM
Human Genome Sciences, Inc. announced financial results for the quarter and full-year periods ended December 31, 2005, and reiterated guidance for financial results anticipated for 2006.Save to My Web